华盛顿州 的 非小细胞肺癌 临床试验
华盛顿州 有 84 项针对 非小细胞肺癌 的研究正在招募参与者。
华盛顿州 的城市
官方研究文本（英文）
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- University of Washington - Fred Hutchinson Cancer Center, Seattle
- Compass Oncology, Vancouver
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月30日 · NCT06765109A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Local Institution - 0384, Spokane
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月30日 · NCT07361510Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Valley Medical Center, Renton
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月30日 · NCT04267848Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
- Vista Oncology - East Olympia /ID# 275438, Olympia
- Northwest Medical Specialties Tacoma /ID# 270469, Tacoma
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月29日 · NCT06772623Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Swedish Cancer Institute-Edmonds, Edmonds
- Swedish Cancer Institute-Issaquah, Issaquah
- Swedish Medical Center-First Hill, Seattle
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月29日 · NCT06498635A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Swedish Cancer Institute ( Site 0143), Seattle
- St. Joseph Medical Center Hematology and Oncology - Silverdale ( Site 0192), Silverdale
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月28日 · NCT06623422A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- American Oncology Network Vista Oncology Division-West office, Olympia
- American Oncology Network Vista Oncology Division-East office, Olympia
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月28日 · NCT07144280A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
- Swedish Cancer Institute, Seattle
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月28日 · NCT05498428Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Northwest Cancer Specialists, P.C., Vancouver
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT07222566This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- American Oncology Network Vista Oncology Division-West office, Olympia
- American Oncology Network Vista Oncology Division-East office, Olympia
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT06758401A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- Research Site, Aberdeen
- Research Site, Renton
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT06868277A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Vista Oncology Inc PS, Olympia
招募中3 期
18 至 100 岁 · 所有性别 · 更新于 2026年9月25日 · NCT05920356A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Vista Oncology, Olympia
- Summit Cancer Centers, Spokane
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT06667076Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Fred Hutchinson Cancer Center, Seattle
招募中观察性研究
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT04981119A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Fred Hutchinson Cancer Center. /ID# 277939, Seattle
- Northwest Cancer Specialists - Vancouver /ID# 277855, Vancouver
招募中2/3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT07155187Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- Fred Hutchinson Cancer Center, Seattle
- University of Washington Medical Center - Montlake, Seattle
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月24日 · NCT03191149Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Swedish Cancer Institute - Edmonds, Edmonds
- Swedish Medical Center, Seattle
- Cancer Care Northwest - Vercler, Spokane Valley
- 以及另外 1 项
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月24日 · NCT06890598Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Northwest Medical Specialties, Tacoma
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月24日 · NCT06047379Pan-tumor MRD Study
- Northwest Medical Specialties (NWMS), Tacoma
招募中观察性研究
18 岁及以上 · 所有性别 · 更新于 2026年9月24日 · NCT06605404Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- Research Site, Edmonds
- Research Site, Seattle
招募中2 期
18 至 95 岁 · 所有性别 · 更新于 2026年9月23日 · NCT05061550Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Research Site, Tacoma
- Research Site, Vancouver
- Research Site, Wenatchee
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月23日 · NCT06357533A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- Swedish Medical Center, Seattle
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月23日 · NCT06618287A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Local Institution - 0515, Edmonds
- Local Institution - 0499, Lacey
- Local Institution - 0508, Seattle
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月23日 · NCT06561386Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
- University of Washington Fred Hutchinson Cancer Center, Seattle
招募中1/2 期
18 至 99 岁 · 所有性别 · 更新于 2026年9月22日 · NCT06814496A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Valley Medical Center /ID# 253950, Renton
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月22日 · NCT04928846A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Medical Oncology Associates - Spokane /ID# 277172, Spokane
- Northwest Medical Specialties Tacoma /ID# 270534, Tacoma
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月22日 · NCT06568939Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- University of Washington Fred Hutchinson, Seattle
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年9月21日 · NCT05983432A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Research Site, Olympia
- Research Site, Seattle
- Research Site, Spokane
- 以及另外 1 项
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月18日 · NCT06692738Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Clinical Study Site, Seattle
- Clinical Study Site, Vancouver
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月18日 · NCT06767514A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
- Fred Hutchison Cancer Center, Seattle
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月18日 · NCT06855771Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Fred Hutchinson Cancer Research Center, Seattle
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月16日 · NCT05786924Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- USOR - Northwest Cancer Specialists, P.C. dba Compass Oncology - Vancouver Cancer Center, Vancouver
招募中2/3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月16日 · NCT04613596The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- University of Washington, Fred Hutchinson Cancer Center, Seattle
招募中1/2 期
12 岁及以上 · 所有性别 · 更新于 2026年9月15日 · NCT04585750Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
- Summit Cancer Treatment Center, Spokane
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月15日 · NCT06899126Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Vista Oncology - East Olympia /ID# 262303, Olympia
招募中2/3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月14日 · NCT06236438FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- Providence Sacred Heart Medical Center, Spokane
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月14日 · NCT06303505Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
- University of Washington (Data Collection Only), Seattle
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月11日 · NCT04410796A Study of KK2269 in Adult Participants With Solid Tumors
- University of Washington, Seattle
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年9月10日 · NCT06266299Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- Fred Hutchinson Cancer Center, Seattle
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年9月9日 · NCT06625775A Phase 1/1b Study of IAM1363 in HER2 Cancers
- Fred Hutchinson Cancer Center, Seattle
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年9月9日 · NCT06253871数据来自 ClinicalTrials.gov，检索日期：2026年10月1日。每项研究自行设定入选标准，由研究团队决定谁能参与。